Cairo – Roche Diagnostics Egypt has signed a Memorandum of Understanding (MoU) with the Egyptian Authority for Unified ...

Results from the Phase III SUNMO trial show that the Lunsumio and Polivy combination achieved statistically significant ...

Roche has demonstrated the power of combining two of oncology’s hottest modalities—bispecifics and antibody-drug conjugates ...

MAIA Biotechnology Inc., a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Roche and Genentech have announced outcomes from the randomised, multi-centre, international Phase III SUNMO trial.

The pharma group has presented phase 1/2 results with new candidate NXT007 at the International Society on Thrombosis and ...

The commercial and clinical use of Elevidys was discontinued after two fatal cases of acute liver failure.

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

A suit cannot be maintained under the Civil law, merely based on an apprehension of litigation, without any concrete or ...

The decision to advance prasinezumab to Phase III was based on results from the Phase IIb PADOVA trial, which demonstrated ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...